129Xe MRI scans

Preclinical

SSean Fain

129Xe MRI scans is one of 3 therapeutic programs targeting Lung. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

LungRecruiting

LungPreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Lung

#DrugCompanyPhaseTrials

Cytalux

OOn Target Laboratories, LLC

Phase 3

1 2

Luvometinib

SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 2

1 3

129Xe MRI scans

SSean Fain

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Lung

NCT06406777

Clinical

Trials by Indication[1]

Lung1 trial

Validation of MRI, CT and Pulmonary Function Tests for Early Detection of Chronic Lung Allograft Dysfunction

Recruiting·SSean Fain·Preclinical·NCT06406777·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 129Xe MRI scans. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 129Xe MRI scans. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sean Fain company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SSean Fain

129Xe MRI scans

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Lung1 trial

References

Drug Info

Quick Facts

Related News